InstalabLoading...
InstalabLoading...
If you have ever had an unexplained blood clot, a stroke at an unusually young age, or repeated pregnancy losses that no one can explain, this test looks for a specific cause that standard blood panels completely overlook. Cardiolipin Antibody IgG (aCL IgG) detects whether your immune system is producing antibodies that make your blood more likely to clot in dangerous places, including the veins of your legs, the arteries of your brain, or the small vessels of the placenta.
This antibody is one of the key markers for a condition called antiphospholipid syndrome (APS), an autoimmune disorder where the body's own defense system turns against certain fats and proteins on cell surfaces, triggering a chain of events that promotes clotting. Knowing your aCL IgG level can explain past events, predict future risk, and guide treatment decisions that reduce the chance of another clot or pregnancy complication.
Cardiolipin is a fat molecule (a type of phospholipid) that sits in the membranes of your cells, especially inside the energy-producing compartments called mitochondria. In a healthy immune system, your body ignores this molecule. In some people, the immune system mistakenly creates antibodies against cardiolipin, specifically against the combination of cardiolipin and a blood protein called beta-2 glycoprotein I (β2GPI).
These antibodies do not measure a normal body function the way cholesterol or blood sugar tests do. Instead, they detect an autoimmune, clot-promoting state. When these antibodies bind to their targets on blood vessel walls and on the surface of platelets (the small cell fragments that help blood clot), they trigger clotting in places it should not happen. The IgG version of this antibody is more strongly linked to clinical problems than the IgM version, which is why labs often report IgG results separately.
The strongest and most consistent association with aCL IgG is thrombosis, the medical term for blood clots forming inside blood vessels. In a systematic review of the antiphospholipid antibody literature, aCL IgG at medium or high levels was identified as a risk factor for both venous clots (such as deep vein thrombosis and pulmonary embolism) and arterial clots (such as stroke). The risk was strongest when aCL IgG appeared alongside another clotting marker called lupus anticoagulant (LA).
In people with lupus (systemic lupus erythematosus, or SLE), a study of 100 patients found that those with IgG anticardiolipin antibodies were significantly more likely to develop blood clots and low platelet counts (a condition called thrombocytopenia, where you do not have enough of the cells that help blood clot normally). A separate study of 58 SLE patients who were aCL positive showed that having lupus anticoagulant alongside aCL IgG made the combination even more specific for predicting blood clotting events.
For people with established coronary artery disease, elevated aCL IgG roughly doubles the risk of experiencing another major cardiac event within one to two years. A meta-analysis pooling data from multiple studies found this association held at both the 12-month and 24-month mark, with even higher risk in people who developed coronary disease before age 50.
Stroke and transient ischemic attack (TIA, sometimes called a "mini-stroke") also show a clear connection. In a study of 110 patients with stroke or TIA, 8.2% had elevated IgG anticardiolipin antibodies, with the highest frequency in younger patients. A separate prospective study of 132 patients who had already experienced a stroke found that those with aCL IgG above 40 GPL (the standard unit for this test) had a higher risk of subsequent clotting events and death.
If your aCL IgG comes back elevated and you have a history of a clot or cardiovascular event, that result reframes your risk profile. It suggests an immune-driven cause rather than the typical cholesterol or blood pressure driven story, and it changes what treatment looks like.
A meta-analysis of heart ultrasound studies in SLE patients found that antiphospholipid antibodies, including aCL IgG, significantly increase the risk of heart valve disease, including a specific type of valve inflammation called Libman-Sacks endocarditis. This means the antibody's effects extend beyond blood clots in large vessels to structural changes in the heart itself.
Pregnancy is one of the areas where this test has the most direct impact on clinical decisions. Even low levels of aCL IgG (below the 40 GPL threshold used for formal APS diagnosis) are associated with higher rates of pregnancy complications, including preeclampsia, fetal growth restriction, preterm birth, and stillbirth. A large cohort study of over 3,000 pregnancies found that this association was driven by the IgG version of the antibody, not IgM.
In a prospective study of 451 low-risk pregnant women, IgG anticardiolipin was the only antiphospholipid antibody strongly associated with fetal loss. The risk was highest when multiple antiphospholipid antibodies were present together, a pattern sometimes called "triple positivity" (aCL plus anti-β2GPI plus lupus anticoagulant), which tracks with worse pregnancy outcomes across multiple studies.
If you have experienced recurrent pregnancy loss and your standard workup has come back normal, this test can identify a treatable cause. Women found to have aCL IgG positivity during pregnancy may benefit from anticoagulant therapy, and knowing the result early changes how a pregnancy is managed from the start.
Not every positive aCL IgG result means you have an autoimmune condition. Infections, most notably COVID-19, can trigger temporary production of these antibodies. A meta-analysis found that antiphospholipid antibodies appear in a large share of hospitalized COVID-19 patients, but these are typically low-level, short-lived, and target different parts of the cardiolipin-β2GPI complex than the antibodies seen in true APS. They do not appear to drive the same clotting risk as the persistent antibodies found in autoimmune patients.
One notable exception involves Q fever, a bacterial infection. A study of 72 patients found that high IgG anticardiolipin levels during acute Q fever independently predicted progression to Q fever endocarditis (infection of the heart valves), suggesting the antibody may have a specific role in certain infectious contexts.
The key distinction is persistence. A single positive result during or shortly after an infection often resolves on its own and does not carry the same meaning as a positive result confirmed at least 12 weeks later.
Cardiolipin IgG results are reported in GPL units (named after the IgG PhosphoLipid standard used to calibrate the test). The thresholds below come from international APS classification criteria and large validation studies. They were developed primarily using ELISA tests (a common laboratory method for detecting antibodies). If your lab uses a different method, such as a chemiluminescent immunoassay (CLIA) or multiplex flow immunoassay, the numeric cutoffs may differ, and your lab should provide its own reference range.
| Level | GPL Units | What It Suggests |
|---|---|---|
| Negative | Below 20 GPL | No significant anticardiolipin IgG detected. Low risk for antibody-driven clotting. |
| Low Positive | 20 to 39 GPL | Below the formal APS classification threshold, but associated with pregnancy complications in large cohort data. Warrants repeat testing and clinical correlation. |
| Medium Positive | 40 to 79 GPL | Meets the threshold for APS classification criteria. Associated with increased clotting and pregnancy risk. |
| High Positive | 80 GPL or above | Strongest association with clotting events, recurrent cardiac events, and pregnancy complications. Typically prompts treatment. |
A study of 190 APS patients found that using the 99th percentile of a healthy population as the cutoff (rather than the fixed 40 GPL threshold) was more sensitive for identifying patients with APS, particularly those with pregnancy-related complications. This means a result in the "low positive" range may still be clinically meaningful, especially in the context of pregnancy loss or unexplained clotting. Compare your results within the same lab over time, since different labs and test platforms can produce different numbers for the same sample.
The biggest source of confusion with this test is not biology but laboratory methodology. Different testing platforms (ELISA, CLIA, multiplex) give substantially different numbers for the same blood sample. A study of over 1,100 samples tested across multiple platforms found poor agreement in classifying results as low, medium, or high positive. The clinical associations were consistent regardless of platform, but the raw numbers were not. This means you should always compare results from the same lab using the same method, and be cautious about comparing a result from one lab to a threshold published by a study that used a different test method.
Acute infections are the other major confounder. COVID-19, other viral infections, and some bacterial infections can produce transient aCL IgG that resolves within weeks to months. A single positive result during or shortly after an illness should always be confirmed with a repeat test at least 12 weeks later before being used to make treatment decisions. Studies of COVID-19 patients showed these infection-related antibodies have different binding characteristics than the persistent antibodies seen in true APS and do not carry the same clotting risk.
This test specifically measures the IgG version of the anticardiolipin antibody. Research consistently shows that IgG aCL is more strongly linked to clotting events than IgM aCL. A study of over 1,000 APS patients found that IgM antiphospholipid antibodies added diagnostic value only in women with obstetric APS, not in people with clot-related APS. In most clinical settings, the IgG result carries more weight for predicting clotting risk. If your lab reports both IgG and IgM results, focus your attention on the IgG number.
A single aCL IgG measurement is a starting point, not a verdict. The formal APS classification criteria require that a positive result be confirmed on a second test drawn at least 12 weeks after the first. This waiting period exists because transient positivity from infections or other triggers is common, and only persistent positivity carries the serious risk associations described above.
A study tracking 204 patients with antiphospholipid antibodies over time found that results remained stable for at least three quarters of subsequent tests, regardless of which laboratory performed the analysis. This means that once you have a confirmed persistent positive, the level tends to stay in a similar range, and meaningful changes in your number over time may reflect real shifts in your immune activity.
If your first test is positive, retest in 12 weeks to confirm persistence. If confirmed positive, retest at least annually to monitor your level. If you are making treatment changes (such as starting anticoagulation or immune-modulating therapy), retesting at 3- to 6-month intervals can help you and your physician gauge whether the approach is working.
A confirmed positive aCL IgG should prompt a broader evaluation, not panic. The next steps depend on your clinical picture.
Cardiolipin Antibody IgG is best interpreted alongside these tests.